Search results for "HERA"

showing 10 items of 14928 documents

Is Caretta Caretta a Carrier of Antibiotic Resistance in the Mediterranean Sea?

2020

Sea turtles can be considered a sentinel species for monitoring the health of marine ecosystems, acting, at the same time, as a carrier of microorganisms. Indeed, sea turtles can acquire the microbiota from their reproductive sites and feeding, contributing to the diffusion of antibiotic-resistant strains to uncontaminated environments. This study aims to unveil the presence of antibiotic-resistant bacteria in (i) loggerhead sea turtles stranded along the coast of Sicily (Mediterranean Sea), (ii) unhatched and/or hatched eggs, (iii) sand from the turtles&rsquo

0301 basic medicineMicrobiology (medical)antibiotic resistance030106 microbiologyZoologyheavy metal resistanceIntegronAntibiotic resistance Caretta caretta Mediterranean SeaBiochemistryMicrobiologyLoggerhead sea turtleArticleantimicrobials03 medical and health sciencesAntibiotic resistanceMediterranean seacaretta carettamedicineMediterranean SeaPharmacology (medical)Marine ecosystemGeneral Pharmacology Toxicology and Pharmaceuticsbiologymobile elementfungilcsh:RM1-950<i>caretta caretta</i>biology.organism_classificationloggerhead sea turtle030104 developmental biologyInfectious Diseaseslcsh:Therapeutics. PharmacologyAeromonasbiology.proteinColistinSeawatermedicine.drugAntibiotics
researchProduct

Comparison of Antibiotic Resistance Profile and Biofilm Production of Staphylococcus aureus Isolates Derived from Human Specimens and Animal-Derived …

2019

Background: The diffusion of antimicrobial resistance is a significant concern for public health worldwide. Staphylococcus aureus represents a paradigm microorganism for antibiotic resistance in that resistant strains appear within a decade after the introduction of new antibiotics. Methods: Fourteen S. aureus isolates from human specimens and twenty-one from samples of animal origin, were compared for their antimicrobial resistance and biofilm capability. In addition, they were characterized at the molecular level to detect the antimicrobial resistance mecA gene and genes related with enterotoxin, toxin, and biofilm production. Results: Both phenotypic and molecular analysis showed main di…

0301 basic medicineMicrobiology (medical)antibiotic resistancemedicine.drug_class030106 microbiologyAntibiotics<i>Staphylococcus aureus</i>VirulenceMRSAEnterotoxinBiologymedicine.disease_causeBiochemistryMicrobiologyMicrobiology03 medical and health sciencesAntibiotic resistancemedicinePharmacology (medical)mecAGeneral Pharmacology Toxicology and PharmaceuticsToxinStaphylococcal toxinsSCCmeclcsh:RM1-950Biofilmbiofilm activitylcsh:Therapeutics. Pharmacology030104 developmental biologyInfectious DiseasesStaphylococcus aureusStaphylococcus aureuStaphylococcal toxinAntibiotics
researchProduct

Using GFP-Tagged Escherichia coli to Investigate the Persistence of Fecal Bacteria in Vegetated Wetlands: An Experimental Approach

2020

The contamination of surface water by pathogenic bacteria of human origin is an important public health issue. Wetlands can be contaminated with fecal bacteria by water originating from different sources, such as wastewater treatment plants and agriculture. Escherichia coli is a commensal of the human gut flora and the major indication of fecal contamination in surface water. Little is known about the association between fecal bacteria and submerged macrophytes and how this may influence the water quality. We questioned whether macrophytes enhance or inhibit the bacterial growth in wetlands. For this purpose, we grew four different species of macrophytes (Mentha aquatica, Baldellia ranuncul…

0301 basic medicineMicrobiology (medical)antimicrobial compoundantimicrobial compounds[SDE.MCG]Environmental Sciences/Global ChangesElodea canadensisWetland010501 environmental sciencesmedicine.disease_causeGFP01 natural sciencesBiochemistryMicrobiologywetlands03 medical and health sciencesAquatic plantBotanymedicineEscherichia coliPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsEscherichia coliComputingMilieux_MISCELLANEOUS0105 earth and related environmental sciences[SDV.EE]Life Sciences [q-bio]/Ecology environmentgeographymacrophytegeography.geographical_feature_categorybiology<i>Escherichia coli</i>lcsh:RM1-950food and beverages15. Life on landbiology.organism_classification6. Clean waterSparganium emersumwetlandMacrophytemacrophytesFecal coliform030104 developmental biologyInfectious Diseaseslcsh:Therapeutics. Pharmacology[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitologyfecal bacteriaWater quality
researchProduct

Would Kinetic Analyses of Plasma Cytomegalovirus DNA Load Help to Reach Consensus Criteria for Triggering the Initiation of Preemptive Antiviral Ther…

2016

0301 basic medicineMicrobiology (medical)business.industry030106 microbiologyAntiviral therapyConsensus criteriaBioinformaticsCytomegalovirus DNA03 medical and health sciences0302 clinical medicineInfectious DiseasesText miningMedicine030212 general & internal medicinebusinessClinical Infectious Diseases
researchProduct

Complex Regulatory Networks Governing Production of the Glycopeptide A40926

2018

Glycopeptides (GPAs) are an important class of antibiotics, with vancomycin and teicoplanin being used in the last 40 years as drugs of last resort to treat infections caused by Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus. A few new GPAs have since reached the market. One of them is dalbavancin, a derivative of A40926 produced by the actinomycete Nonomuraea sp. ATCC 39727, recently classified as N. gerenzanensis. This review summarizes what we currently know on the multilevel regulatory processes governing production of the glycopeptide A40926 and the different approaches used to increase antibiotic yields. Some nutrients, e.g., valine, l-glutamine and mal…

0301 basic medicineMicrobiology (medical)medicine.drug_class030106 microbiologyAntibioticsInfectious DiseaseReviewGlycopeptide antibioticBiologyLuxR solomedicine.disease_causeBiochemistryMicrobiologyMicrobiology03 medical and health sciencesStrRValinemedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsA40926Regulatory geneRegulator geneTeicoplaninlcsh:RM1-950DalbavancinLALA40926; Dalbavancin; Dbv cluster; Glycopeptide antibiotics; LAL; LuxR solo; Regulatory genes; StrR; Microbiology; Biochemistry; Pharmacology Toxicology and Pharmaceutics (all); Microbiology (medical); Infectious Diseases; Pharmacology (medical)regulatory genesGlycopeptidelcsh:Therapeutics. PharmacologyInfectious DiseasesDalbavancinStaphylococcus aureusPharmacology Toxicology and Pharmaceutics (all)Dbv clusterVancomycinglycopeptide antibioticsmedicine.drugAntibiotics
researchProduct

Characteristics and Management of Candidaemia Episodes in an Established Candida auris Outbreak

2020

The multi-resistant yeast Candida auris has become a global public health threat because of its ease to persist and spread in clinical environments, especially in intensive care units. One of the most severe manifestations of invasive candidiasis is candidaemia, whose epidemiology has evolved to more resistant non-albicansCandida species, such as C. auris. It is crucial to establish infection control policies in order to control an outbreak due to nosocomial pathogens, including the implementation of screening colonisation studies. We describe here our experience in managing a C. auris outbreak lasting more than two and a half years which, despite our efforts in establishing control measure…

0301 basic medicineMicrobiology (medical)medicine.medical_specialty<i>Candida auris</i>colonisation030106 microbiologymultidrug-resistantyeastBiochemistryMicrobiology03 medical and health sciences0302 clinical medicineInternal medicineIntensive careAmphotericin BEpidemiologyInfection controlMedicinecandidaemiaPharmacology (medical)030212 general & internal medicineGeneral Pharmacology Toxicology and Pharmaceuticsoutbreakbusiness.industryMortality ratelcsh:RM1-950Outbreaklcsh:Therapeutics. PharmacologyInfectious DiseasesCandida aurissurveillancefungibusinessFluconazolemedicine.drugAntibiotics
researchProduct

Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation.

2019

Introduction: Infections are among the most frequent complications in patients with hematological and oncological diseases. They might be classified as fever of unknown origin and microbiologically or clinically documented infections. Optimal duration of antimicrobial treatment is still unclear in these patients.Areas covered: We provide an overview on the management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation.Expert opinion: Patients with febrile high-risk neutropenia should be treated empirically with an anti-pseudomonal agent such as piperacillin/tazobactam. Several clinical studies support the assumption that the primary antibiotic regime…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyAntifungal Agents030106 microbiologyNeutropeniaMicrobiologyTazobactam03 medical and health sciencesAntimicrobial Stewardship0302 clinical medicineAnti-Infective AgentsVirologyMedicineHumans030212 general & internal medicineFever of unknown originIntensive care medicineFebrile Neutropeniabusiness.industryDrug Resistance Microbialmedicine.diseaseAntimicrobialDrug Resistance MultipleDiscontinuationAnti-Bacterial AgentsInfectious DiseasesDrug Therapy CombinationbusinessFebrile neutropeniaDe-escalationmedicine.drugPiperacillinExpert review of anti-infective therapy
researchProduct

Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)

2021

Abstract Scope Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become pandemic, reaching almost one million death worldwide. At present standard treatment for coronavirus disease 2019 (COVID-19) is not well defined because the evidence, either from randomized or observational studies, with conflicting results, has led to rapid changes in treatment guidelines. Our aim was to narratively summarize the available literature on the management of COVID-19 in order to combine current evidence and interpretation of the data by experts who are treating patients in the frontline setting. Methods The panel conducted a detailed review of the literature and eventual press rele…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)030106 microbiologyCoronavirupractice guidelines as topiccoronavirusrandomized controlled trials as topicGuidelinesmedicine.disease_causemedicallaw.invention03 medical and health sciences0302 clinical medicinesocietiesRandomized controlled triallawPandemicitalymedicinepneumonia030212 general & internal medicineIntensive care medicinehumansSocieties MedicalCoronavirustherapySARS-CoV-2business.industryCOVID-19; Coronavirus; Pneumonia; SARS-CoV-2; TherapyStandard treatmentCOVID-19PneumoniaGeneral Medicinecovid-19; coronavirus; pneumonia; sars-cov-2; therapy; covid-19; humans; italy; randomized controlled trials as topic; sars-cov-2; societies medical; standard of care; practice guidelines as topicCOVID-19 Drug TreatmentCoronavirusClinical trialsars-cov-2Infectious Diseasescovid-19standard of carePosition paperObservational studyTherapyCoronavirus; COVID-19; Pneumonia; SARS-CoV-2; TherapybusinessHuman
researchProduct

Phage Therapy in Livestock and Companion Animals

2021

The irrational use of antibiotics has led to a high emergence of multi-drug resistant (MDR) bacteria. The traditional overuse of antibiotics in the animal feed industry plays a crucial role in the emergence of these pathogens that pose both economic and health problems. In addition, antibiotics have also recently experienced an increase to treat companion animal infections, promoting the emergence of MDR bacteria in pets, which can reach humans. Phages have been proposed as an alternative for antibiotics for the treatment of livestock and companion animal infections due to their multiple advantages as adaptative drugs, such as their ability to evolve, to multiply at the site of infections, …

0301 basic medicineMicrobiology (medical)phage therapyPhage therapyCoronavirus disease 2019 (COVID-19)Phage therapymedicine.drug_classAnimal feedVeterinary medicineCompanion animalmedicine.medical_treatment030106 microbiologyAntibioticsRM1-950ReviewBiologyAntimicrobial resistanceBiochemistryMicrobiologyantibiotics03 medical and health sciencesHealth problemsAntibiotic resistanceAntibioticsmedicinePharmacology (medical)antimicrobial resistanceGeneral Pharmacology Toxicology and Pharmaceuticsbusiness.industryBiotechnologyveterinary medicine030104 developmental biologyInfectious DiseasesLivestockTherapeutics. PharmacologybusinessAntibiotics
researchProduct

Directed evolution of a Mycobacteriophage

2019

This article belongs to the Special Issue Bacteriophages: Alternatives to Antibiotics and Beyond.

0301 basic medicineMicrobiology (medical)phage therapyPhage therapyPhage therapyMycobacteriophagemedicine.medical_treatment030106 microbiologymycobacteriophagesMycobacterium smegmatismedicine.disease_causeBiochemistryMicrobiologyArticle03 medical and health sciencesAntibiotic resistancemedicinePharmacology (medical)General Pharmacology Toxicology and Pharmaceuticsdirected evolutionGeneticsMycobacteriophagesbiologyMycobacterium smegmatislcsh:RM1-950Pathogenic bacteriaMycobacteriophagesbiology.organism_classificationDirected evolution3. Good health030104 developmental biologyInfectious Diseaseslcsh:Therapeutics. PharmacologyLytic cycle<i>Mycobacterium smegmatis</i>Directed evolution
researchProduct